Chemours: Buying the PFAS Discount, Then Moving Out the Curve

The Trade

Chemours senior unsecured paper traded wide of BB/B materials credits carrying similar leverage. The gap was compensation for two risks, PFAS litigation and a TiO₂ trough, that the balance sheet could already absorb. The thesis did not require a recovery, only that nothing else had to go right.

The credit was pitched twice, four weeks apart, at two points on the curve: first at UCLA Anderson's Fink Center Credit Pitch Competition, then at UNC Kenan-Flagler's Alpha Challenge.

	UCLA · 07-Nov-25	UNC · 03-Dec-25
Security	CC 5.75% 11/15/28	CC 4.625% 11/15/29
Price	95.3	87.1
Yield	7.5%	8.5%
OAS	+394	+520
OAS duration	2.6	3.5
vs. BB/B materials	+150	+250
Target OAS	+301	+428
Compression	93bp	92bp
Target total return	9.4%	11.2%

Both pitches used the same thesis on the same issuer at the same seniority. The December pitch is the November analysis acted on.

Moving Out the Curve

The UCLA deck priced the PFAS premium separately at each point on the curve, and it was not flat: roughly +150bp on the 2028s, +200bp on the 2029s, and +150bp on the 2033s against the fitted market curve. We pitched the 2028s in November because the shorter tenor made the carry easier to defend in a bear case, but the analysis put the largest mispricing one maturity further out.

By early December there was more to work with. Q3 numbers had landed: LTM EBITDA $793mm against $789mm, net income positive at $151mm after a $412mm LTM loss the prior quarter, cash up to $613mm, and net leverage down to 4.6x. TSS grew 80% year over year in the quarter against 65% the quarter before, and the 2026E Opteon revenue mix moved from 60% to 70%. The deleveraging leg of the thesis was no longer a projection.

That mattered more for the 2029s than the 2028s. The premium the market charged was for a litigation tail resolving over years, so it was concentrated in tenor, and visibly improving fundamentals made the additional duration worth owning. The 2029s offered 88bp more OAS than the 2028s for less than a year of additional spread duration, on the same obligor and the same claim.

The Alpha Challenge screened its eligible universe rather than allowing a free pick: US public issuers rated BB+ to CC+, at least $300mm outstanding, yielding above 5%, maturing between 30-Oct-2029 and 31-Oct-2035. The 2028s failed the maturity floor by eleven months and were not eligible. Chemours had two bonds on the list, the 4.625% 2029s and the 8% 2033s, and the November work had already measured the wider residual on the 2029s at +200 against +150 on the 2033s. The constraint removed the November pick. It did not pick the replacement.

The December pitch moved out the curve: buy the 4.625% 2029s at 87.1 and +520, target +428 for an 11.2% total return. Wider spread, more duration, and the same 92bp of compression required to get paid.

How It Played Out

Marked as of 08-Aug-2026.

	Pitched	08-Aug-26	Target	Total return
CC 5.75% 11/28	95.27	98.88	98.5	+8.3%
CC 4.625% 11/29	87.10	94.44	92.2	+12.0%

Both are through target price with months left on a one-year horizon. The 2028s returned about 8.3% in nine months, from 3.61 points of price and 4.33 of carry on a 95.27 basis. The 2029s returned about 12.0% in eight months, from 7.34 points of price and 3.15 of carry on 87.10, which annualizes near 18%.

Holding the start date constant gives a cleaner test. Priced off the December cap table, when both bonds were live options on the same screen:

From 03-Dec-25	Entry	08-Aug-26	Price	Carry	Total
CC 5.75% 11/28	95.06	98.88	+3.82	+3.91	+8.1%
CC 4.625% 11/29	87.10	94.44	+7.34	+3.15	+12.0%

The issuer, seniority and window are identical, so the 390bp difference is attributable to the tranche decision alone. The curve compressed in the shape the regression predicted: yields fell 209bp on the 2029s where the measured premium was widest, 126bp on the 2028s, and 66bp on the 2033s.

Part of what the tranche decision bought was headroom. The 2028 indenture calls at 101.917% from November 2025 and 100.958% from November 2026, so that paper's upside was bounded near 101 regardless of how the credit performed. The covenant appendix in the November deck flagged it at the time, in the note that the near-term call premium caps upside on a short-term hold. The ceiling never bound, since the 2028s reached 98.88 against a 100.958 call, but it was there from the start and the 2029s at 87.1 had nothing equivalent above them. Owning a bond whose return is limited by its call schedule rather than by its credit is the same objection the XPO memo raises against that issuer's unsecured notes.

Two caveats. Those are yield moves rather than spread moves, so part of the compression is the Treasury curve rather than credit, and a clean attribution needs the curve on both dates. The price and total return figures carry no such assumption. Separately, the 2028 tranche has shrunk from $782.6mm to $594.6mm, so Chemours has been retiring this maturity with cash, which is the deleveraging path the base case required.

Why the Bonds Were Cheap

Opteon economics. Thermal & Specialized Solutions sells low-GWP refrigerants into a patent-protected duopoly with Honeywell running through 2030, against mandated phase-downs of high-GWP HFCs under the U.S. AIM Act and the EU F-Gas Directive. Customer HVAC and automotive systems are engineered around a specific refrigerant, so switching costs are high and demand is scheduled by regulation. The Corpus Christi expansion had already lifted Opteon capacity 40% and was complete, leaving the capex behind the company and the cash flow ahead of it. TSS was modeled from $571mm of segment EBITDA in 2024 to $738mm in 2026E at a 33% margin.

The cyclical segment was already at the bottom. Titanium Technologies averaged 23% EBITDA margins from 2013–2022 and was running near 7% on pigment prices at cycle lows, with housing starts down roughly 28% from the 2022 peak. The base case assumed no recovery, holding TT margins at about 10% against that 23% historical average, and the credit still deleveraged to mid-3x on TSS growth alone, helped by a $250mm cost-reduction program and the Taiwan plant closure. TiO₂ recovery was upside rather than a requirement. Every $100/ton move in pigment is worth about $110mm of annual EBITDA, so the upside was material, but the bonds worked without it.

PFAS exposure was bounded and documented. The MOU with DuPont and Corteva caps shared liability at $4B gross with a 50/50 cost split, of which $2.6B was already spent, leaving roughly $1.4B of shared headroom plus $225mm of unused insurance. The $875mm New Jersey consent order is nominal over 25 years, roughly $500mm NPV with half to Chemours, and requires no out-of-pocket cash before 2030 because insurance monetization and existing escrow fund it. Base case litigation and remediation cash was $50mm a year and bear case $125mm. Against $1.5B of liquidity, neither number threatens a 2028 or 2029 maturity.

Isolating the PFAS Premium

The relative value argument had to survive the objection that Chemours trades wide because it deserves to. Rather than eyeball a comp table, we regressed bond spread on net leverage and interest coverage, correcting for maturity, across the specialty chemicals and materials complex.

Issuer	Security	Spread	Net lev.	(EBITDA − capex) / int
Avient	AVNT 7⅛ 08/30	158	3.7x	5.3x
Olin	OLN 5⅝ 08/29	171	3.7x	3.6x
HB Fuller	FUL 4¼ 10/28	185	3.9x	3.9x
Celanese	CE 6.85 11/28	220	7.3x	2.1x
Compass Minerals	CMP 8 07/30	309	4.9x	1.4x
Huntsman	HUN 4½ 05/29	344	5.8x	3.2x
Chemours	CC 5¾ 11/28	394	4.7x	1.8x

The model fit at an R² of 0.841 and predicted +242 for the 2028s against +394 actual. The residual of about 150bp is what the market was charging for PFAS and TiO₂ headline risk beyond what the credit metrics justified, and the trade rests on that number. Quantifying it made the position falsifiable, since the bonds only needed the premium to compress toward the fitted curve. It also made the comparison across the curve possible, which produced the December switch.

Forecasting the same model forward on 2026 base case metrics gave +201, and we declined to assume the premium disappeared. Adding back 100bp of residual PFAS charge produced the +301 target on the 2028s. The bear case ran the same model in reverse, at 6.5x leverage, 1.2x coverage, a fitted +497, and a widening of the premium to 200bp for +697. It still cleared a positive total return, because a 5.75% coupon on a three-year bond carries a large amount of income against a price decline.

Downside

Two independent floors, since the litigation tail is the one risk that does not respond to operating performance.

Going concern. At 6.5x on $910mm of base case EBITDA, enterprise value is $5.9B against $1.5B of secured claims, and unsecured recovers par. Stressing the multiple to 5.5x on $577mm of bear case EBITDA leaves unsecured recovering 50%. Capitalizing $2.8B of PFAS claim value ahead of the notes as an unsecured pari claim still leaves 87% recovery on base case enterprise value, and 33% in a bear case with the tail on top.

Liquidation. Marking assets down to 70–80% recovery on inventory and 35–45% on net PP&E, and running trustee fees, wind-down and contingency through the waterfall, senior secured is covered in full and total unsecured recovers 32–44%. That is the floor, and neither 95 nor 87 is close to it.

Documentation

The notes are senior unsecured, structurally subordinated to the credit facilities, and guaranteed by all material domestic restricted subsidiaries. What protects the unsecured cushion is the secured debt cap, which limits secured debt to the greater of $3.20B or a 2.50:1.00 consolidated net secured leverage ratio, with a general lien basket permitting a further 15% of consolidated net tangible assets outside the primary facility capacity. The bear case has secured net leverage peaking near 1.9x, inside that test, so the cap leaves room. It is a defined limit rather than an open one, which is the distinction that matters when the risk you are underwriting is a claim that could rank ahead of you.

Two events of default sit at low thresholds for a credit carrying active litigation. Cross-acceleration triggers at $100mm of other debt accelerated on default. Judgment default triggers at a $100mm unstayed judgment, net of insurance, unpaid for 60 days. That is why the settlement structure mattered as much to the thesis as the settlement amounts: 25-year payment schedules and insurance-funded near-term obligations keep any single adverse outcome away from the judgment threshold rather than relying on the total staying small.

The change of control put is weaker than it reads. It requires a repurchase offer at 101% plus accrued interest, but only on a double trigger, meaning a change of control followed by a downgrade or ratings review within 60 days. Reporting failure becomes an event of default after 120 days.

What Would Have Broken It

TiO₂ moving from depressed to recessionary was the most direct bear path. TSS at $738mm of 2026E segment EBITDA more than covers TT at $237mm, and anti-dumping duties in the U.S. and EU put a floor under pigment pricing against Chinese supply.

The genuine tail is the MOU cap. Below $4B of gross claims Chemours pays half. Above it, Chemours pays all of the excess with no further cost-sharing and only insurance as cushion. The unsettled matters that could reach it are AFFF personal injury claims in the MDL, roughly 100 opt-out water systems, and state natural resource damage claims. All are disclosed as reasonably possible but not accruable, which is why the market charged a premium for them, and why the argument was that the premium was too large rather than unwarranted.

Extending from the 2028s to the 2029s bought more of that tail, which is the cost of the December decision. A 3.5-year spread duration compounds a widening as efficiently as a tightening, so the bear case on the 2029s is worse than on the 2028s. The position was that the premium was too large in the tenor where the market had concentrated it.

Attribution

Pitched as Team Delta for UCLA Anderson at the Fink Center Credit Pitch Competition on 07-Nov-2025, with Hailee Arst, Gus Guenther and Andrew McAllister.

The competition is national. The field includes Wharton, Chicago Booth, Columbia, Yale, NYU Stern, Kellogg, Haas, Darden, Tuck and London Business School, and teams pitch a single long or short in a specific corporate credit instrument rather than a company. The Fink Center records the 2025–26 result as UCLA Anderson first, Columbia second and USC Marshall third.

The credit was pitched again at UNC Kenan-Flagler's Alpha Challenge on 03-Dec-2025, where I presented solo. The Alpha Challenge is also national, in its 22nd year, and runs credit and equity tracks for MBA teams from top programs. I can speak to every number in both decks.

Both decks are published with this piece: the UCLA deck on the 2028s, with the quarterly model, covenant analysis, settlement history and doomsday cash-drain scenario, and the UNC deck on the 2029s.